Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | Unknown | — |
The patient received booster of Rabavert after 30 years; Case reference number US-BN-2025-000902 is a spontaneous case report initially received from a other health care professional via MedCommunication (reference number: USBAV25-1011) on 02-May-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, as reported, 30 years ago, the patient had primary series of RabAvert vaccine along with prefilled syringe, needle for injection and injection for reconstitution (batch number: unknown) at an unknown dose, route and site of administration for unknown indication. On 02-May-2025, as reported 30 years after first dose, the patient received first booster dose of RabAvert vaccine along with prefilled syringe, needle for injection and injection for reconstitution (batch number: unknown) at an unknown dose, route and site of administration (explicitly coded as 'Inappropriate schedule of vaccine administration'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A female patient of unspecified age received first booster dose of RabAvert vaccine for unknown indication, as reported 30 years after first dose, which is considered as inappropriate schedule of vaccine administration. It was unknown if the patient experienced any adverse events due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age received first booster dose of RabAvert vaccine for unknown indication, as reported 30 years after first dose, which is considered as inappropriate schedule of vaccine administration. It was unknown if the patient experienced any adverse events due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.